Table 1 The correlation between DAPK1 expression and clinicopathological features of 125 OV patients
From: Anoikis-related signature predicts prognosis and characterizes immune landscape of ovarian cancer
Characteristic | No. of patients | DAPK1 expression | p-value | |
|---|---|---|---|---|
Low (IRS score < 6) | High (IRS score ≥ 6) | |||
Age (n, %) | Â | Â | Â | 0.855 |
 < 55 years | 56(44.8%) | 39(31.2%) | 17(13.6%) | – |
 ≥ 55 years | 69(55.2%) | 47(37.6%) | 22(17.6%) | – |
FIGO stage (n, %) | Â | Â | Â | 0.002 |
 I–II | 45(36.0%) | 39(31.2%) | 6(4.8%) | – |
 III–IV | 80(64.0%) | 47(37.6%) | 33(26.4%) | – |
Pathology stage (n, %) | Â | Â | Â | 0.953 |
 I–II | 54(43.2%) | 37(29.6%) | 17(13.6%) | – |
 III | 71(56.8%) | 49(39.2%) | 22(17.6%) | – |
Histology type (n, %) | Â | Â | Â | 0.331 |
 Serous | 78(62.4%) | 53(42.4%) | 25(20.0%) | – |
 Mucous | 11(8.8%) | 10(8.0%) | 1(0.8%) | – |
 Endometrioid | 14(11.2%) | 8(6.4%) | 6(4.8%) | – |
 Other types | 22(17.6%) | 15(12.0%) | 7(5.6%) | – |
Tumor diameter (n, %) | Â | Â | Â | 0.604 |
 < 10 cm | 62(49.6%) | 44(35.2%) | 18(14.4%) | – |
 ≥ 10 cm | 63(50.4%) | 42(33.6%) | 21(16.8%) | – |
Serum CA125 (n, %) | Â | Â | Â | 0.051 |
 < 35 U/ml | 20(16.0%) | 18(14.4%) | 2(1.6%) | – |
 ≥ 35 U/ml | 105(84.0%) | 68(54.4%) | 37(29.6%) | – |